Retrophin (RTRX) PT Raised to $32 at Leerink Partners Following Clear Efficacy from Sparsentan
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Leerink Partners analyst Joseph Schwatz reiterated an Outperform rating and boosted his price target on Retrophin (NASDAQ: RTRX) to $32.00 (from $27.00) after the company announced positive top-line results for Phase 2b DUET study of sparsentan in focal segmental glomerulosclerosis (FSGS) this morning and they spoke with management following the results conference.
"We are very optimistic that sparsentan will be approved but it remains to be seen whether today's results will support accelerated approval (AA) or if another clinical trial is needed," Schwatz said.
Shares of Retrophin closed at $16.32 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Cowen Downgrades Under Armour, Inc. (UA) to Market Perform
- RBC Capital Cuts Price Target on Pentair (PNR) to $66 Following 3Q Report
- Imperial Capital Raises Price Target on Spirit Airlines (SAVE); Cuts 4Q Estimates
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!